The detrimental relationship between treatment with TNF inhibitors and demyelinating diseases has been extensively analysed, and a large burden of evidence supports the association, even though exposure to anti-TNF-α seems to carry a not so burdensome hazard of MS. This evidence concerns the gene TNF and myeloid sarcoma.